Uracil/tegafur plus oral calcium folinate in advanced breast cancer

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Richardet, Eduardo Arnoldo, Pedraza, Cecilia, Mickiewicz, Elizabeth, Lerzo, Guillermo, Bonamasa, Miguel, Coppola, Federico, Elli, Alicia, Uranga, Graciela, Jovtis, Silvia, Bruno, Mario, Ventriglia, Mónica, Cuevas, María Andrea
Formato: Artículo
Lenguaje:Español
Publicado: 1999
Materias:
Acceso en línea:http://pa.bibdigital.ucc.edu.ar/3734/1/A_Richardet_Pedraza_Mickiewicz_Bonamasa_Coppola_Elli_Uranga_Jovtis_Bruno_Ventriglia_Cuevas.pdf
Aporte de:
id I38-R144-3734
record_format dspace
spelling I38-R144-37342025-04-11T22:21:48Z http://pa.bibdigital.ucc.edu.ar/3734/ Uracil/tegafur plus oral calcium folinate in advanced breast cancer Richardet, Eduardo Arnoldo Pedraza, Cecilia Mickiewicz, Elizabeth Lerzo, Guillermo Bonamasa, Miguel Coppola, Federico Elli, Alicia Uranga, Graciela Jovtis, Silvia Bruno, Mario Ventriglia, Mónica Cuevas, María Andrea R Medicina (General) Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase H trial investigating the feasibility of 250 mg/m2/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation. 1999-12-31 info:eu-repo/semantics/article info:eu-repo/semantics/closedAccess application/pdf spa http://pa.bibdigital.ucc.edu.ar/3734/1/A_Richardet_Pedraza_Mickiewicz_Bonamasa_Coppola_Elli_Uranga_Jovtis_Bruno_Ventriglia_Cuevas.pdf Richardet, Eduardo Arnoldo, Pedraza, Cecilia, Mickiewicz, Elizabeth, Lerzo, Guillermo, Bonamasa, Miguel, Coppola, Federico, Elli, Alicia, Uranga, Graciela, Jovtis, Silvia, Bruno, Mario, Ventriglia, Mónica and Cuevas, María Andrea (1999) Uracil/tegafur plus oral calcium folinate in advanced breast cancer. Oncology, 13 (7). pp. 96-97. ISSN 0890-9091
institution Universidad Católica de Córdoba
institution_str I-38
repository_str R-144
collection Producción Académica Universidad Católica de Córdoba (UCCor)
language Español
orig_language_str_mv spa
topic R Medicina (General)
spellingShingle R Medicina (General)
Richardet, Eduardo Arnoldo
Pedraza, Cecilia
Mickiewicz, Elizabeth
Lerzo, Guillermo
Bonamasa, Miguel
Coppola, Federico
Elli, Alicia
Uranga, Graciela
Jovtis, Silvia
Bruno, Mario
Ventriglia, Mónica
Cuevas, María Andrea
Uracil/tegafur plus oral calcium folinate in advanced breast cancer
topic_facet R Medicina (General)
description Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase H trial investigating the feasibility of 250 mg/m2/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation.
format Artículo
author Richardet, Eduardo Arnoldo
Pedraza, Cecilia
Mickiewicz, Elizabeth
Lerzo, Guillermo
Bonamasa, Miguel
Coppola, Federico
Elli, Alicia
Uranga, Graciela
Jovtis, Silvia
Bruno, Mario
Ventriglia, Mónica
Cuevas, María Andrea
author_facet Richardet, Eduardo Arnoldo
Pedraza, Cecilia
Mickiewicz, Elizabeth
Lerzo, Guillermo
Bonamasa, Miguel
Coppola, Federico
Elli, Alicia
Uranga, Graciela
Jovtis, Silvia
Bruno, Mario
Ventriglia, Mónica
Cuevas, María Andrea
author_sort Richardet, Eduardo Arnoldo
title Uracil/tegafur plus oral calcium folinate in advanced breast cancer
title_short Uracil/tegafur plus oral calcium folinate in advanced breast cancer
title_full Uracil/tegafur plus oral calcium folinate in advanced breast cancer
title_fullStr Uracil/tegafur plus oral calcium folinate in advanced breast cancer
title_full_unstemmed Uracil/tegafur plus oral calcium folinate in advanced breast cancer
title_sort uracil/tegafur plus oral calcium folinate in advanced breast cancer
publishDate 1999
url http://pa.bibdigital.ucc.edu.ar/3734/1/A_Richardet_Pedraza_Mickiewicz_Bonamasa_Coppola_Elli_Uranga_Jovtis_Bruno_Ventriglia_Cuevas.pdf
work_keys_str_mv AT richardeteduardoarnoldo uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT pedrazacecilia uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT mickiewiczelizabeth uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT lerzoguillermo uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT bonamasamiguel uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT coppolafederico uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT ellialicia uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT urangagraciela uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT jovtissilvia uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT brunomario uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT ventrigliamonica uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
AT cuevasmariaandrea uraciltegafurplusoralcalciumfolinateinadvancedbreastcancer
_version_ 1832592364468699136